The FDA has given the green light to Sunharbo, the brand name for asundexian, a once-daily pill aimed at lowering the chance of another stroke in certain adults. In a large international trial, the drug cut repeat ischemic stroke risk by 26% when added to standard antiplatelet treatment, while also showing some important safety caveats that doctors will be watching closely.
The medicine is meant for people who recently had a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, also known as a TIA. That means it is not for every stroke patient, especially those whose strokes came from atrial fibrillation or a heart valve problem.
Asundexian works in a different lane from many older blood-thinning drugs. It targets factor XIa, a protein that helps drive clot formation, and that more focused approach is part of why it has drawn so much attention.
Dr. Richard Kovacs, a cardiologist at Indiana University School of Medicine and chief medical officer of the American College of Cardiology, said the drug blocks a very specific part of the clotting process. That narrower target is appealing because it may reduce clotting without opening the door to the same level of bleeding risk seen with some older therapies.
The approval was backed by a phase 3 randomized study that enrolled 12,327 patients across 37 countries. Every participant had recently dealt with either an ischemic stroke or a high-risk TIA, and they were followed for an average of about 14.2 months.
Patients took 50 mg of asundexian once a day along with antiplatelet therapy, often aspirin, while the comparison group received a placebo plus the same background treatment. That setup gave researchers a clear look at whether the new drug added real protection on top of standard care.
The numbers were encouraging. About 6.6% of people on asundexian had another stroke, compared with 8.8% in the placebo group, and the medication also lowered the combined risk of cardiovascular death, heart attack, or stroke.
There was also a reduction in deaths from any cause, with 10.5% in the treatment group versus 12.3% in the placebo group. Those results suggest the drug may be doing more than just trimming stroke risk, though it still does not erase the danger completely.
Bleeding is the big issue that always hangs over drugs in this category. The trial did not show a major overall spike in serious bleeding, but gastrointestinal bleeding was more common, and major bleeding rose in patients over 75 during the first 90 days.
That matters because stroke survivors are often already dealing with fragile health and multiple medications. Doctors will likely use extra caution in older patients and anyone with a tougher medical history.
The study was published in The New England Journal of Medicine on Nov. 9, and it was funded by Bayer, which makes asundexian. Like many large trials, it had limits, including a relatively short follow-up window for judging long-term safety and durability.
Researchers also left out certain patients with heart conditions and more severe strokes. That means the real-world picture may end up being a little messier than the trial data alone suggests.
Kovacs stressed that timing matters, because the drug was used very soon after the stroke in the study, often within 72 hours. That makes early conversations with the care team especially important, ideally while the patient is still in the hospital or just after discharge.
There is also a bigger lesson here that goes beyond one pill. Stroke prevention is still built on the basics, including blood pressure control, cholesterol management, exercise, healthy food, and quitting smoking.
Many of these strokes are tied to atherosclerosis, the slow buildup of plaque that narrows blood vessels and chokes off blood flow to the brain. In that sense, the new drug is one more tool, not a replacement for the habits and treatments that keep arteries from getting worse.
Stroke remains a huge problem in the United States, with more than 795,000 cases each year and roughly 185,000 occurring in people who have already had one before. Since about one in four survivors experiences another stroke within five years, even a modest drop in risk can carry real weight for patients trying to stay ahead of the next one.
